Cutaneous manifestations are frequent and diverse among patients with rheumatoid arthritis and impact their quality of life: a cross-sectional study in a cohort of patients with recent-onset disease

Sánchez-Cardenas, Gabriela; Contreras-Yáñez, Irazú; Guaracha-Basáñez, Guillermo; Pacheco-Santiago, Lexli D; Méndez‐Flores, Silvia; Barrera‐Vargas, Ana; Merayo-Chalico, Javier; Domínguez‐Cherit, Judith; Pascual‐Ramos, Virginia

doi:10.1007/s10067-021-05664-0

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Musculoskeletal ultrasonography and synovial biopsies could not correctly evaluate the effects of the applied therapies, which is why the use of other diagnostic methods and therapeutic evaluation tools are required in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) (14). Changes in the skin induced by RA or PsA are scarcely studied (15,16). Data from the literature regarding the reactivity of the skin in RA and PsA before or after therapy are also extremely limited (17).…”

mentioning

confidence: 99%

CLIC1 Expression in Skin Biopsies from Patients With Rheumatoid and Psoriatic Arthritis as a Potential Tool to Predict Therapy Response

Bordean

Copotoiu

Raica

et al. 2021

In Vivo

View full text Add to dashboard Cite

Background/Aim: Chloride intracellular channel protein 1 (CLIC1) activates inflammasomes in rheumatoid (RA) and psoriatic (PsA) arthritis. We studied CLIC1 expression in RA and PsA patients' skin with vasculitis and its variability depending on the therapy used. Materials and Methods: CLIC1 immunoexpression was evaluated in the vascular (CLIC1-V) and stromal (CLIC1-S) compartments of the RA and PsA skin biopsies of patients treated with methotrexate (MTX), leflunomid (LFN), corticotherapy (CT), or biological therapies. Results: MTX significantly reduced CLIC1-S expression (p=0.016), whereas LFN decreased CLIC1-V (p<0.001). LFN therapy duration also correlated with CLIC1-V (p<0.001). CT decreased CLIC1-S expression (p=0.006). CLIC1-S expression persisted in skin biopsies despite of erythrocyte sedimentation rate (ESR, p=0.018) and C reactive protein (CRP, p=0.0026) normalisation. For PsA, CLIC1-S expression significantly related to MTX (p<0.022). Both CLIC1-S (p<0.001) and CLIC1-V (p=0.007) decreased by biological therapies in RA. Conclusion: CLIC1 expression is strongly influenced by the therapy used. Our data strongly support the extensive evaluation of CLIC1 in RA as a potential marker of inflammation and tool to predict therapy response.Chloride intracellular channel protein 1 (CLIC1) is a member of the CLICs family, and one of the most conserved proteins (1). It was first cloned due to its increased expression in activated macrophages (2). CLIC1, also known as NCC27, has an early and variable expression in human fetal tissues, and is found in low levels in human fetal brain but in high levels in the human fetal lung, kidney, and liver (3). During human adult life, expression variability persists among most human tissues (4). The intracellular chloride channels are membrane bound and participate in different pathological processes including inflammation associated with neurodegenerative diseases (5)atherosclerosis (6) ankylosing spondylitis (7) tumor progression, and metastasis of urinary bladder cancer (8) renal cell carcinomas (9) or hepatocellular carcinomas (10). CLIC1 has a high translocation ability between the cytoplasmic and nuclear compartments depending on the functional status and based on this translocation; CLIC1 functions are extremely versatile (11). These versatile functions of chloride channels such as CLIC1 include the regulation of cellular metabolism by acting at the 2559 This article is freely accessible online.

show abstract

mentioning

confidence: 99%